66 results about "Cholangeitis" patented technology

The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.

Disclosed are methods and compositions for treatment of a subject having a biliary disorder. The methods include administering a therapeutically effective amount of a serine protease inhibitor to a subject in need thereof. The biliary disorder include biliary atresia, a biliopathy, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), and combinations thereof. In certain aspects, the serine protease inhibitor may be a protease inhibitor rC1 Inhibitor.

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; or liver damage arising from fibrosis.

The invention provides a Chinese medicine preparation for treating cholecystitis and cholangitis. The preparation comprises, by weight, 100-200 parts of mung bean soaking in fresh cattle bile, 50-60 parts of radices saussureae, 20-30 parts of scutellaria baicalensism, 25-30 parts of cape jasmine, 20-30 parts of stigmata maydis, 20-25 parts of serrate rabdosia herb, 15-20 parts of artemisiacapillarisThunb, 20-30 parts of common andrographis, 20-25 parts of desmodium, 15-20 parts of medicated leaven, 15-20 parts of ventriculi galli mucosa, 15-20 parts licorice, and 15-20 parts of radix gentianae. The preparation can be used for treating cholecystitis and cholangitis with the effectiveness higher than 80%.

The invention belongs to the field of medical detection, and relates to a serum exosome PIGR, specifically to a use for using serum exosome pIgR as a marker for diagnosing primary biliary cholangitisand predicting curative effect. The technical solution adopted by the invention is a kit for using serum exosome pIgR as a marker for diagnosing primary biliary cholangitis and predicting curative effect, which is characterized by including the following components: a pIgR standard, a polystyrene ELISA (Enzyme Linked Immunosorbent Assay) microplate coated with pIgR antigens, a second enzyme-labeled antibody, a sample diluent, and an auxiliary reagent. The technical solution of the application method of the kit includes the following steps of: (1) preparing the sample diluent; (2) diluting thepIgR standard with a BSA-PBS solution into 8 gradients; (3) adding the standard and the sample diluent to a microplate; (4) adding the second enzyme-labeled antibody to each well; (5) adding a color developing liquid to each well; and (6) using a microplate reader to read an OD value at a wavelength of 450 nm , drawing a standard curve, and converting pIgR concentration in the sample. New kits andapplications are implemented by employing the above schemes.

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.